Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransMedics GroupTMDX -2.66%69 Cyclically Adjusted PS Ratio is 16.12 as of Jul. 18, 2026, which is 45% below its 10-year median of 29.19. GuruFocus rates TMDX with a GF Score™ of 69/100 and a GF Value™ of $169.41 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 523 Medical Devices & Instruments companies, TransMedics Group ranks worse than 94.46% on this metric.
The historical rank and industry rank for TransMedics Group's Cyclically Adjusted PS Ratio or its related term are showing as below:
TMDX'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 16.11 Med: 29.19 Max: 31.65
Current: 16.11
During the past 10 years, TransMedics Group's highest Cyclically Adjusted PS Ratio was 31.65. The lowest was 16.11. And the median was 29.19.
TMDX's Cyclically Adjusted PS Ratio is ranked worse than 94.46% of 523
companies
in the Medical Devices & Instruments industry
Industry Median: 2.28
vs TMDX: 16.11
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
TransMedics Group's adjusted revenue per share data of for the fiscal year that ended in Dec25 was $14.935. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.59 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
TransMedics Group (NAS:TMDX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
TransMedics Group Cyclically Adjusted PS Ratio Related Terms
TransMedics Group Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for TransMedics Group's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group Cyclically Adjusted PS Ratio Chart
TMDX vs AXGN, BFLY, ESTA: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, TransMedics Group's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where TransMedics Group's Cyclically Adjusted PS Ratio falls into.
TransMedics Group Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
TransMedics Group's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 16.12 mean?
TransMedics Group (TMDX) has a Cyclically Adjusted PS Ratio of 16.12 as of Jul. 18, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on TransMedics Group and its competitors. This is 45% below median its historical median of 29.19. Over the past decade, TransMedics Group's Cyclically Adjusted PS Ratio has ranged from 16.11 to 31.65. According to the industry distribution chart, TransMedics Group ranks #494 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 94.5%.
Is TransMedics Group's Cyclically Adjusted PS Ratio too high?
TransMedics Group's current Cyclically Adjusted PS Ratio of 16.12 is 45% below median its 10-year median of 29.19. Over the past 10 years, this metric has ranged from a low of 16.11 to a high of 31.65. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.28. TransMedics Group's value of 16.12 is 607% above this industry median. Based on the distribution chart, TransMedics Group ranks #494 out of 523 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's Cyclically Adjusted PS Ratio compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #494 out of 523 companies for Cyclically Adjusted PS Ratio. This places TransMedics Group in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.28. TransMedics Group's value of 16.12 is 607% above this benchmark. Historically, TransMedics Group's own Cyclically Adjusted PS Ratio has ranged from 16.11 to 31.65 over the past decade. While the company's 10-year median is 29.19 vs. the industry median of 2.28, TransMedics Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.28, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current Cyclically Adjusted PS Ratio of 16.12 is 607% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current Cyclically Adjusted PS Ratio is 16.12, which is 45% below median its own 10-year median of 29.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $169.41, compared to a current price of $73.98 — trading 56.3% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 16.12, which is 45% below median its 10-year median of 29.19 and 607% above the Medical Devices & Instruments industry median of 2.28. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For TransMedics Group (TMDX), the current Cyclically Adjusted PS Ratio is 16.12 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $73.98 is trading 56.3% below its estimated GF Value™ of $169.41.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
Cyclically Adjusted PS Ratio: 16.12 (45% below median its 10-year median of 29.19)
GF Value™: $169.41 vs. price of $73.98 (56.3% below fair value)
Industry Position: 607% above the Medical Devices & Instruments median (#494 of 523)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for TMDX
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
